HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer

Elena A. Pudova†, Anna V. Kudryavtseva†, Maria S. Fedorova, Andrew R. Zaretsky, Dmitry S. Shcherbo, Elena N. Lukyanova, Anatoly Y. Popov, Asiya F. Sadritdinova, Ivan S. Abramov, Sergey L. Kharitonov, George S. Krasnov, Kseniya M. Klimina, Nadezhda V. Volchenko, Nataliya V. Melnikova, Maria A. Chernichenko, Dmitry V. Sidorov, Boris Y. Alekseev, Marina V. Kiseleva, Andrey D. Kaprin, Alexey A. Dmitriev and Anastasiya V. Snezhkina*

From Belyaev Conference
Novosibirsk, Russia. 07-10 August 2017

Abstract

Background: Colorectal cancer (CRC) is a common cancer worldwide. The main cause of death in CRC includes tumor progression and metastasis. At molecular level, these processes may be triggered by epithelial-mesenchymal transition (EMT) and necessitates specific alterations in cell metabolism. Although several EMT-related metabolic changes have been described in CRC, the mechanism is still poorly understood.

Results: Using CrossHub software, we analyzed RNA-Seq expression profile data of CRC derived from The Cancer Genome Atlas (TCGA) project. Correlation analysis between the change in the expression of genes involved in glycolysis and EMT was performed. We obtained the set of genes with significant correlation coefficients, which included 21 EMT-related genes and a single glycolytic gene, HK3. The mRNA level of these genes was measured in 78 paired colorectal cancer samples by quantitative polymerase chain reaction (qPCR). Upregulation of HK3 and deregulation of 11 genes (COL1A1, TWIST1, NFATC1, GLIPR2, SFPR1, FLNA, GREM1, SFRP2, ZEB2, SPP1, and RARRES1) involved in EMT were found. The results of correlation study showed that the expression of HK3 demonstrated a strong correlation with 7 of the 21 examined genes (ZEB2, GREM1, TGFB3, TGFB1, SNAI2, TWIST1, and COL1A1) in CRC.

Conclusions: Upregulation of HK3 is associated with EMT in CRC and may be a crucial metabolic adaptation for rapid proliferation, survival, and metastases of CRC cells.

Keywords: Warburg effect, Hexokinase, Glycolysis, Colorectal cancer, Epithelial-mesenchymal transition

Background

In 2012, an estimated 1.36 million people were diagnosed with colorectal cancer (CRC), including 746,300 men and 614,300 women. The mortality rate of CRC is reported to be approximately half of its global incidence. In the same year, 694,000 people died from CRC [1], making it the third most common cancer and fourth most common cause of death worldwide [2].

The stage of CRC plays a significant role in survival of patients. More than 60% of patients are diagnosed at late stage of CRC (III-IV) and approximately 25% of them display metastatic disease [3, 4]. Development of new drugs and targeted therapies has dramatically improved the survival of these patients over the last decade [5]. However, the survival outcome in patients with metastatic or stage IV CRC still remains poor [6, 7]. For instance, the 5-year relative survival rate for patients with...
metastatic CRC is about 11%, while that for patients with stage III CRC ranges from 53% to 89% (https://www.cancer.org). CRC is characterized by severe genetic alterations, including microsatellite instability (MSI), epigenetic changes such as DNA methylation (CpG Island Methylator Phenotype [CIMP]), and chromosomal instability (CIN), which are associated with the development of the disease and its aggressive behavior [8, 9]. Thus, identification of the distinct molecular genetic changes related to CRC progression and metastasis is extremely important.

A number of studies have demonstrated that epithelial-mesenchymal transition (EMT) is involved in CRC carcinogenesis and metastasis [10, 11]. EMT is the conversion of epithelial cells into cells with a mesenchymal phenotype, which is accompanied by a decrease in cell-cell cohesion and fundamental reorganization of the cytoskeleton. Consequences include enhanced migratory as well as invasive capacity and resistance to apoptosis [12, 13]. Based on the biological context, three types of EMT have been described as follows: type I observed in embryogenesis [14], type II involved in tissue repair and fibrosis [15], and type III seen in metastatic transformation of cancer cells [16]. A hallmark feature of EMT is the downregulation of E-cadherin, a cell-cell adhesion molecule localized on the surface of epithelial cells [17]. E-cadherin is a well-known tumor suppressor protein and loss of its expression in tumor cells is associated with increased tumor invasiveness and metastasis [18, 19]. In CRC, EMT is characterized by decreased E-cadherin expression and nuclear accumulation of β-catenin, which is an essential protein for correct positioning and function of one [20, 21]. Loss of epithelial and gain of dedifferentiated mesenchymal-like phenotype enable CRC cells to develop invasive and metastatic growth characteristics [22]. The switch from cytoplasmic to nuclear accumulation of β-catenin is a central mechanism related to EMT in CRC [21]. This process may be mediated by the loss-of-function mutations in the adenomatous polyposis coli (APC) tumor suppressor gene or mutations that result in β-catenin stabilization [23]. In the nucleus, β-catenin associates with DNA-binding proteins of the T-cell factor/lymphoid enhancer factor (TCF/LeF) family, leading to a constitutive activation of Wnt/β-catenin signaling target genes, c-Myc [24] and CCND1 [25]. Moreover, β-catenin triggers the expression of other genes such as MMP7 [26, 27], FN [28], CD44 [29], and LPAR [30] involved in invasive cell growth. Except for this mechanism, there are at least ten known signaling pathways and many molecules associated with EMT in CRC [31].

Metabolic reprogramming characterized by upregulated glycolysis is another crucial feature of cancer. It provides cancer cells with energy and metabolites essential for active cell division, large-scale biosynthesis, invasion, and metastasis [32–34]. Increased glycolysis has been suggested as an essential component of the malignant phenotype and hallmark of invasive cancers [35]. In CRC, redirection of glucose metabolism is promoted by deregulation of key components involved in glucose transport (GLUT-1) [36], metabolism (hexokinases [HK1, HK2], pyruvate kinase M2 [PKM2], lactate dehydrogenase A [LDHA], aldolase A [ALDOA], etc.) [37–39], as well as metabolic regulation [40–42]. In addition, variation in the representation of alternative spliced transcripts related to energy metabolism seems to be associated with the prevalence of aerobic glycolysis in cancer cells [43, 44]. EMT in tumors requires the distinct metabolic adaptations for survival, rapid proliferation, and metastasis. However, metabolic changes observed upon EMT induction are uncommon for various cancer types [45–47]. Recent studies showed that the glycolytic enzymes aldolase B (ALDOB), PKM2, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) play a role in EMT and metastasis in CRC [48, 49].

In this work, using CrossHub software we analyzed RNA-Seq data from The Cancer Genome Atlas (TCGA) project to estimate the association between the expression of genes participating in EMT and glycolysis in CRC. Hexokinase 3 (HK3) was found to exhibit significant correlation with a set of genes involved in EMT. Thus, we focused on the investigation of HK3 gene expression in CRC samples and its association with EMT.

**Methods**

**Bioinformatic analysis**

Using CrossHub software [50], we have analyzed The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov) project RNA-Seq dataset derived from CRC. The dataset contained 287 tumor samples including 26 paired ones. The selection of genes participating in glycolysis and EMT was performed using Gene Ontology database and “glycolytic process” and “epithelial to mesenchymal transition” as keywords. A set of 132 genes was selected for further analysis.

The correlation analysis between the expressions of target genes was performed using Spearman’s rank correlation coefficients ($r_s$). We carried out two tests: one for paired samples and other for pool of tumor samples. Spearman’s rank correlation coefficients were calculated between (1) fold change values, the ratio of CPM (counts per million) in tumor sample to CPM in conditional normal tissue, (paired samples) and (2) CPM values (pool of tumor samples). Before calculating correlation coefficients, dropping points (no more than 5%) were eliminated using approximate generalized linear model. We focused on the genes with concordant results in paired and pooled tests.
Tissue samples
In total, 78 paired CRC samples, including tumor and adjacent morphologically normal tissues (conditional normal tissue), were collected from patients in Herzen Moscow Cancer Research Institute - branch of National Medical Research Radiological Center, Ministry of Health of Russian Federation (Moscow, Russia). The sample information is presented in Table 1. Samples were obtained after surgical resection prior to radiation or chemotherapy and were stored in liquid nitrogen. The diagnosis was verified by histopathology, and only samples with 70% or more tumor cells were used in the study. The morphological classification of the tumor was performed according to the WHO Classification of Tumours of the Digestive System (WHO/IARC Classification of Tumours, 4th Edition, 2010) and verified according to the American Joint Committee on Cancer (AJCC) staging system (AJCC Cancer Staging Manual, 8th Edition, 2017). Samples were collected in accordance with the guidelines issued by The Ethics committee of Herzen Moscow Cancer Research Institute. Written informed consent was obtained from all patients.

RNA isolation and reverse transcription
Nitrogen-frozen tissues were homogenized using a Mikro-Dismembrator S (Sartorius, Germany). Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Germany) according to manufacturer’s instructions. Purified RNA was quantified using NanoDrop 1000 (NanoDrop Technologies Inc., USA) and the RNA quality measured with the RNA Integrity Number (RIN) method on Agilent RNA Bioanalyzer 2100 (Agilent Technologies, USA). All RNA samples were treated with RNase-free DNase I (Thermo Scientific). Reverse transcription was performed from 1 μg of total RNA using M-MuLV reverse transcriptase (Thermo Fisher Scientific) and random hexamer primers (Evrogen, Russia). Negative control samples were included in each set of reactions. Reactions were heated at 70 °C for 5 min to melt the secondary structure of mRNA, followed by immediate cooling on ice. Samples were further incubated at 25 °C for 5 min, followed by treatment with M-MuLV reverse transcriptase at 25 °C for 10 min. Then the reaction tubes were incubated at 42 °C for 1 h. Following the incubation, samples were diluted to 48 μL in nuclease-free water and stored at −20 °C.

Quantitative polymerase chain reaction (qPCR)
Quantitative polymerase chain reaction was performed using commercial primer-probe sets for target genes (HK3: Hs01092850_m1, VASN: Hs01936449_s1, GREM1: Hs01879841_s1, TGBF3: Hs01086000_m1, TGBF1: Hs00998133_m1, LOXL3: Hs01046941_g1, HGF: Hs00300159_m1, SNAI2: Hs00161904_m1, FAM101B: Hs00823804_m1, SFRP2: Hs00293258_m1, FLNA: Hs00924645_m1, WWTR1: Hs00210007_m1, SFRP1: Hs00610060_m1, GLI2P2: Hs01555479_m1, NFATC1: Hs00542675_m1, TWIST1: Hs01675818_s1, COL1A1: Hs00164004_m1, ZEB2: Hs00207691_m1, VIM: Hs00958111_m1, TP53: Hs01034249_m1, SPP1: Hs00959010_m1, RARRES1: Hs00894859_m1) from TaqMan Gene Expression Assays (Thermo Fisher Scientific). Primers and probes for reference genes, GUSB and RPN1, were designed earlier [51]. The reactions were carried out on AB 7500 Real-Time PCR System (Thermo Fisher Scientific) as previously described [52]. Each reaction was repeated three times.
QPCR data were analyzed using relative quantification or ΔΔCt-method as previously described [44, 52]. Relative mRNA level of the genes was calculated using ATG program compatible with relative quantification software (Thermo Fisher Scientific) as previously described [52]. Given the variability of mRNA level of the reference gene, an mRNA level change of at least two-fold was considered as significant.

Statistical analysis
Statistical analysis was performed using SPSS 10 software (SPSS Inc., USA). The Wilcoxon/Mann-Whitney and Kruskal-Wallis tests were applied to analyze differences in mRNA expression of target genes in CRC samples. Spearman’s rank correlation coefficient (r_s) was used for revealing correlations. A value of p ≤ 0.05 was considered statistically significant.

Results
Preliminary correlation analysis of gene expression based on TCGA project data
We identified a number of genes that showed high correlations between each other in CRC with the false
discovery rate (FDR) ≤ 0.05. In the heat maps, these genes formed a significant correlation module (Additional file 1: Table S1 and Additional file 2: Table S2). Only one glycolytic gene, HK3, was presented in this module. A significantly strong correlation was observed between HK3 gene and 16 EMT-related genes (VASN, GREM1, TGFB3, TGFB1, LOXL3, HGF, SNAI2, FAM101B, SFRP2, FLNA, WWTR1, SFRP1, GLIPR2, Nfatc1, Twisti, and COL1A1), both in paired as well as pool of tumor samples. In addition, literature data analysis revealed several genes that are involved in EMT process. Preliminary calculation of correlation coefficients between the expression of these genes and HK3 was carried out using CrossHub software and RNA-Seq data from TCGA project as described above. The results obtained are shown in Additional file 3: Table S3 (available only for 26 paired CRC samples). A significant correlation was reported between the change in expression of HK3 gene and five additional genes (ZEB2, VIM, TP53, SPP1, and RARRES1) involved in EMT. Thus, HK3 and a set of 21 EMT-related genes were selected for further assessment by qPCR.

**Upregulation of HK3 gene expression in CRC**

Using qPCR, we quantified the expression of HK3 gene in 78 paired CRC samples. HK3 mRNA level was upregulated from 2 to 12-fold in 41% (32/78, $p < 0.01$) CRC samples as compared with that in conditional normal tissue (Fig. 1). Over two-fold decrease in the expression of HK3 gene was determined in 14% (11/78) of cases. The mean value of relative mRNA level was 1.7. HK3 overexpression was not correlated with CRC progression stage.

In addition, we verified the expression of all selected EMT-related genes using qPCR. Deregulation in the expression of 11 genes (COL1A1, TWIST1, Nfatc1, GLIPR2, SFRP1, FLNA, GREM1, SFRP2, ZEB2, SPP1, and RARRES1) was detected in CRC (Table 2). A significant increase ($p < 0.05$) in the mRNA level of COL1A1, TWIST1, CREM1, and SPP1 genes was observed in most examined samples. Moreover, Nfatc1, GLIPR2, SFRP1, FLNA, SFRP2, ZEB2, and RARRES1 genes were downregulated by over two-fold ($p < 0.05$) in more than 40% of CRC cases.

**Correlation study between HK3 and EMT-related genes in CRC**

In order to determine the correlation between HK3 and EMT-related genes, Spearman’s rank correlation coefficients were calculated. The results obtained are shown in Table 3. We found a significantly strong correlation ($> 0.5$ or $< -0.5$, $p < 0.05$) between HK3 mRNA level and expression of seven of 21 examined genes (ZEB2, GREM1, TGFB3, TGFB1, SNAI2, TWIST1, and COL1A1) in CRC. Generally, HK3 gene expression was positively correlated with almost all tested genes at moderate or weak levels. A negative correlation was detected between HK3 and TP53 genes only.

**Discussion**

In the 1920s, Otto Warburg and co-workers observed the altered energy metabolism in proliferating tumor cells. These cells were shown to exhibit increased glycolysis with lactate secretion even in the presence of oxygen — a phenomenon known as the “Warburg effect” [53]. Increased glucose metabolism, now considered as a hallmark of cancer, is thought to be essential for tumor cell growth, survival, proliferation, and long-term maintenance [54]. The first step of glycolysis is catalyzed by hexokinases (HKs). There are four HK isoenzymes encoded by separate genes, HK1, HK2, HK3, and HK4 (or GCK) [55]. HKs phosphorylate glucose to glucose 6-phosphate using ATP molecule as the phosphoryl donor [56]. HKs are the first rate-limiting enzymes of glycolysis. Alterations in their expression promote changes in glucose flux. Overexpression of HK1 and HK2 genes was reported in many tumors

---

**Fig. 1** Relative mRNA level of HK3 gene in colorectal cancer (qPCR data). The mRNA level of HK3 was normalized by those of two reference genes, GUSB and RPN1. Data were presented according to CRC progression stage.
including colorectal, prostate, breast, lung, gastrointestinal, and pancreatic cancers [39, 57–61]. In particular, HK2 expression was suggested to be responsible for accelerated glycolysis in cancer cells [62]. Nevertheless, activities of both HK1 and HK2 are essential for their survival [63]. Association of HK4 expression with tumorigenesis is still unclear. However, polymorphisms in HK4 and HK2 affect the risk and clinical outcome in pancreatic cancer [64, 65]. A recent study reported functional role of HK3 in acute promyelocytic leukemia [66, 67]. No other studies have described the role of HK3 in human cancers. This is the first study to report HK3 upregulation in CRC and its potential association with EMT.

The loss of E-cadherin expression during EMT is a major event in cancer. Downregulation of E-cadherin is mediated by a series of transcription repressors, including proteins of the SNAIL superfamily (SNAI1, SNAI2, and SNAI3) and ZEB family (ZEB1 and ZEB2), forkhead-box protein FOXC2, factors E47 and KLF8, and TWIST bHLH proteins (TWIST1 and TWIST2) [68]. Upregulation of major EMT transcription factors such as TWIST1, ZEB1, ZEB2, SNAI1, and SNAI2 has been observed in many tumors [69–77]. We showed an increased expression of TWIST1 gene in CRC, as reported in a previous study [78]. Furthermore, overexpression of TWIST1 was demonstrated to promote migration and invasion of CRC cells and induce EMT. Although no significant upregulation in SNAI2 mRNA level was observed in this work, SNAI2 protein expression was earlier shown to be upregulated in colorectal tumors [77]. Shioiri and co-authors demonstrated the localization of overexpressed SNAI2 protein in the cytoplasm, wherein its gene-repressive function is absent [79]. We also reported downregulation of ZEB2 gene in more than half of CRC samples, while its overexpression was observed at the invasion front of CRC in another study [80]. However, ZEB2 protein promotes EMT progression through direct suppression of the transcription of genes involved in epithelial dedifferentiation [81, 82]. Thus, ZEB2 overexpression may not be generally observed after EMT and may not always correlate with the mesenchymal phenotype [83]. In addition, we found significant positive correlations between the expression of HK3 and TWIST1, SNAI2, and ZEB2 genes in CRC. The association of HK3 with important EMT inducers may indicate its involvement in EMT in colorectal cancer.

The genes TGFβ1 and TGFβ3 encode signaling proteins, transforming growth factor-beta 1 and 3 (TGFβ1 and TGFβ3). These are secreted ligands of specific TGFβ membrane receptors that play an essential role during differentiation, proliferation, and embryonic development in normal tissues. In general, the binding of the ligand to its receptor initiates phosphorylation of proteins belonging to the SMAD family. Activated SMAD proteins assemble into complexes with transcription factors to directly regulate gene expression [84]. Many studies have demonstrated the involvement of TGFβs in EMT during normal development and pathological

### Table 2

| Gene   | Frequency of mRNA level changes, % | Median of mRNA level changes, n-fold |
|--------|-----------------------------------|-------------------------------------|
| COL1A1 | 79.5 (62/78)                      | 5 (4/78)                            |
| TWIST1 | 67 (52/78)                        | 4 (3/78)                            |
| NFATC1 | 9 (7/78)                          | 50 (39/78)                          |
| GLIPR2 | 0 (0/78)                          | 74 (58/78)                          |
| SFPR1  | 4 (3/78)                          | 82 (64/78)                          |
| FLNA   | 15 (12/78)                        | 44 (34/78)                          |
| GREM1  | 53 (41/78)                        | 20.5 (16/78)                       |
| SFRP2  | 23 (18/78)                        | 46 (36/78)                          |
| ZEB2   | 3 (2/78)                          | 55 (43/78)                          |
| SPP1   | 76 (59/78)                        | 5 (4/78)                            |
| RARRES1| 9 (7/78)                          | 63 (49/78)                          |

Note: QPCR data. ↑↓: mRNA level decrease/increase

### Table 3

| Gene       | Correlation coefficient, $r_s$ |
|------------|-------------------------------|
| ZEB2       | 0.62*                         |
| VIM        | 0.49*                         |
| VASN       | 0.33*                         |
| GREM1      | 0.51*                         |
| LOXL3      | 0.39*                         |
| HGF        | 0.20                          |
| TPS3       | −0.47*                        |
| TGFβ3      | 0.57*                         |
| TGFβ1      | 0.59*                         |
| SNAI2      | 0.58*                         |
| SPP1       | 0.44*                         |
| RARRES1    | 0.35*                         |
| SFRP2      | 0.39*                         |
| FLNA       | 0.12                          |
| WWTR1      | 0.15                          |
| SFPR1      | 0.29                          |
| GLIPR2     | 0.23                          |
| NFATC1     | 0.42*                         |
| TWIST1     | 0.52*                         |
| COL1A1     | 0.53*                         |
| FAM101B    | 0.48*                         |

*-$p < 0.05$
Thus, HK3 gene expression was observed in breast cancer samples with TP53 mutations, as per TCGA data [112]. In this study, CRC samples were not tested for TP53 mutations, but could also be positive for ones.

Conclusions
We showed the upregulation of HK3 gene in CRC and confirmed its involvement in tumorigenesis. Expression of HK3 gene significantly correlated with mRNA levels of important EMT transcriptional factors (ZEB2, TGFB3, TGFB1, SNAI2, and TWIST1) and components (GREM1 and COL1A1). Thus, our study suggests that HK3 may participate in EMT process and that its upregulation could be one of the crucial changes for adaptation of glucose metabolism to EMT in CRC.

Additional files

Additional file 1: Table S1. (XLS 393 kb)
Additional file 2: Table S2. (XLS 389 kb)
Additional file 3: Table S3. (XLS 34 kb)

Acknowledgments
Authors thank National Medical Research Center of Radiology, Pletnev State Hospital, and Pirogov Russian National Research Medical University for supplying samples; Vavilov Institute of General Genetics for the assistance in data analysis; Initium-Pharm, LTD for providing computational resources. This work was performed using the equipment of BMBBBS AS “Genome” center (http://www.embr.ru/rus/ckp/ccu_genome_c.php).

Funding
This work and publication costs were funded by the Russian Science Foundation, grant 14–15–01083.

Availability of data and materials
All data generated or analyzed during this study is included in this published article and its supplementary information files.

About this supplement
This article has been published as part of BMC Genomics Volume 19 Supplement 3, 2018: Selected articles from Belyaev Conference 2017: Genomics. The full contents of the supplement are available online at https://bmcgenomics.biomedcentral.com/articles/supplements/volume-19-supplement-3.

Authors’ contributions
EAP, AVK, ARZ, AAD, and AVS conceived and designed the work; EAP, MSF, AF, ISA, SLK, NNW, KWN, MAC, DSS, DVS, and AVS performed the experiments; ENL, EAP, AVK, ARZ, GSK, KWN, AAD, MSF, KMK, AYP, MKV, NVK, and AVS analyzed the data; EAP, AVK, ADK, BYA, AAD, and AVS wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by The Ethics committee of Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation. The study was done in accordance with the principles outlined in the Declaration of Helsinki (1964).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Haggard FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in colon and rectal surgery. 2009;22(4):191–7.
3. Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. Opin Cell Biol. 1997;9(5):683–90.
4. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, 3rd, Blanke CD, Harris J, Gutman DJ, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2010, 15(10):1079–90.
5. De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. The role of epithelial-mesenchymal transition of colorectal cancer. World J Gastroenterol. 2010, 16(33):5312–9.
6. Parwati, K., Pirtle, L.M., Vrabel, V., et al. Genetic manipulation and targeted therapies in colorectal cancer. Cancer Chemother Pharmacol. 2008, 61(3):291–300.
7. Lagerkvist, A., Lindahl, L., Ullberg, K., et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Cycle. 2015, 14(11):1766–417.
8. Hay ED. An overview of epithelial-mesenchymal transformation. Acta Anat. 1995;154(1):1–19.
9. Kudryavtseva AV, Lipatova AV, Zaretsky AR, Moskalev AA, Fedorova MS, Kudryavtseva AV, Lakunina VA, Snezhkina AV, Volchenko NN, et al. Downregulation of OGDHL expression is associated with promoter methylation and poor prognosis. Int J Oncol. 2017;50(2):525–34.
10. Melnikova NV, Poteryakhina AV, Nyushko KM, Belyakov MM, Kaprin AD, et al. Aldolase a is a key regulator of hypoxic adaptation in colorectal cancer cells. Celldeath & differentiation. 2001;9(2):288–96.
11. Kovacheva M, Dayanidhi M, Schmitt J, et al. Identification of c-MYC as a target of the APC tumor suppressor role. Cell. 1991;66(1):107–19.
12. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(2):1776–84.
13. Krasnov GS, Dmitriev AA, Sadtritdinova AF, Fedorova MS, Kudryavtseva AV, Lakunina VA, Snezhkina AV, Volchenko NN, et al. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastases of patients with colorectal cancer. Mol Cell Biochem. 2004;253(1-2):89–97.
14. Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, Lorenzini E, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. The pharmacogenomics journal. 2017;17(3):258–64.
15. Forever SA, Sato-Rothman MA, Molteni JJ, et al. Epithelial-mesenchymal transition in colon carcinoma. Science. 1997;275(5307):1784–7.
16. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, et al. The role of epithelial mesenchymal transition in tumor progression. Nat Rev Cancer. 2004, 4(1):58–69.
17. Phan LM, Yeung SC, Lee MH: Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer biology & medicine. 2014, 11(1):1–19.
18. Crawford HC, Fingleton BD, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. The metalloproteinase matrilysin is a target of beta-catenin-Tcf complex in APC–/– colon carcinoma. Science. 1997;275(5307):1784–7.
19. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, et al. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. PLoS ONE. 2011;6(11):e27533.
20. Secta U. Vegvand, G., Moleb, R., et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.
21. Brabletz T, Jung A, Reu S, Porzner M, Hübeker F, Kunz-Schughart LA, Kneuechel R, Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98(18):10356–61.
22. Kirchner T, Brabletz T. Patternning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol. 2000;157(4):1113–21.
23. Kornek V, Barker N, Morin PJ, van Widen D, de Weger R, Kinder KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC–/– colon carcinoma. Science. 1997;275(5307):1784–7.
42. Mansour RN, Enderami SE, Ardeshirylajimi A, Fooladsaz K, Fathi M, Ganji SM.
Pudova et al. BMC Genomics
46. Masin M, Vazquez J, Rossi S, Groeneveld S, Samson N, Schwalie PC,
44. Dmitriev AA, Kudryavtseva AV, Krasnov GS, Koroban NV, Speranskaya AS,
49. Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K,
51. Krasnov GS, Oparina NY, Dmitriev AA, Kudryavtseva AV, Anedchenko EA,
50. Snezhkina AV, Krasnov GS, Lipatova AV, Sadritdinova AF, Kardymon OL,
53. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to
tumor metabolism, cancer growth and dissemination. A new pH-based
dysregulation of polyamine metabolism in colorectal cancer is associated with
overexpression of c-Myc and C/EBPbeta rather than Enterotoxigenic
bacteroides fragilis infection. Oxidative Med Cell Longev. 2016;2016:253560.
57. He X, Lin X, Cai M, Zheng X, Liu L, Fan D, Wu X, Lan P, Wang J. 
Expression of trefoil factors and TWIST1 in colorectal cancer and their expression in kidney cancer. 
Mol Biol. 2011;45(2):211–20.
58. Melnikova NV, Dmitriev AA, Belenkin MS, Koroban NV, Spersansky AS,
Krivitsina AA, Krasnov GS, Lakunina VA, Shnaiderman VA, Sadritdinova AF, et al. 
Identification, expression analysis, and target prediction of hexokinase Genotropin MicroRNAs under normal and nutrient stress conditions. Front Plant Sci. 2016;7:399.
59. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206(Pt 12):2049–57.
60. Alfarouk KO, Verduzzo D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, 
Koruban NV, Shnaiderman VA, VesevolovskaVA, Dmitriev AA, 
Sechenko VN, Melnikova NV, Spersansky AS, Dairi MV, Stepanov OA, et al. 
Differential expression of genes that encode glycolytic enzymes in kidney and lung cancer in humans. Russ J Genet. 2013;49(7):707–16.
61. Krasnov GS, Dmitriev AA, Lakunina VA, Shnaiderman VA, Sadritdinova AF, et al. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 2014;8(5):1461–74.
62. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Wei RJ, Davis S, 
Stark AM, Markova MJ, Kurik R, et al. Analysis of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Molecular Cancer research: MCR. 2009; 7(9):1438–45.
63. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57(2):170–8.
82. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huykebrecht D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267–76.
83. Beltran M, Puig I, Pena C, Garcia JM, Alvarez AB, Pena R, Bonilla F, de Herreros AG. A natural antisense transcript regulates Zeb2/Sp1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 2008;22(6):756–69.
84. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1(3):169–78.
85. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72.
86. Ignott RA, Massague J. Cell adhesion protein receptors as targets for transforming growth factor-beta action. Cell. 1987;51(2):189–97.
87. Raghov R, Postlthwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest. 1987;79(4):1285–8.
88. Girsch SM, Memoli VA, Stulak TA, Gold LJ, Antick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992;52(4):1694–92.
89. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Markowich S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268(5215):1336–8.
90. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai M, Nagashima R, Miyata H, Takeda H, et al. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Oncol Rep. 2001;7(5):1258–62.
91. Carvajal G, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Ruiz-Otegra M, Egido J, Mezzano S. Gremlin: a novel mediator of epithelial mesenchymal transition in fibrosis. J Rheumatol. 2016;43(3):474–85.
92. Karagiannis GS, Berk A, Dimitromanolakis A, Diamandis EP. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol Oncol. 2013;7(4):826–39.
93. Wang L, Yu P. miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53. Oncol Rep. 2016;36(6):3225–32.
94. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavriloiva O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650–3.
95. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IRX-MF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10(5):E111–8.
96. Han EJ, Yoo SA, Kim GM, Hwang D, Cho CS, You S, Kim WU. GREM1 is a key regulator of Synoviocyte hyperplasia and invasiveness. J Rheumatol. 2016;43(3):474–85.